(Q39190617)

9 September 2017

Huntington's Disease-Update on Treatments (English)

1 reference

9 September 2017

0 references

Kara J Wyant

1

1 reference

PubMed ID

28324302

9 September 2017

Andrew J Ridder

series ordinal

2

1 reference

PubMed ID

28324302

9 September 2017

Praveen Dayalu

series ordinal

3

1 reference

9 September 2017

1 April 2017

1 reference

Current Neurology and Neuroscience Reports

9 September 2017

1 reference

9 September 2017

17

1 reference

9 September 2017

4

1 reference

9 September 2017

33

1 reference

https://scigraph.springernature.com/pub.10.1007/s11910-017-0739-9

9 September 2017

0 references

cites work

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Differential loss of striatal projection neurons in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Analysis of CYP2D6 genotype and response to tetrabenazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

The long-term effect of tetrabenazine in the management of Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

A study of chorea after tetrabenazine withdrawal in patients with Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Letter: Double-blind trial of lithium carbonate and haloperidol in Huntington's chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Clozapine in Huntington's chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Olanzapine for Huntington's disease: an open label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Olanzapine in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Risperidone in chorea and psychosis of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Risperidone in treatment of choreoathetosis of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Quetiapine in Huntington's disease: a first case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Ziprasidone in Huntington's disease: the first case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Amantadine in Huntington's disease: open-label video-blinded study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

A randomized trial of amantadine in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Riluzole in Huntington's disease: a 3-year, randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Deep brain stimulation of the internal pallidum in Huntington's disease patients: clinical outcome and neuronal firing patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Long-term follow-up of pallidal deep brain stimulation in two cases of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Bilateral globus pallidus stimulation for Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Differential and better response to deep brain stimulation of chorea compared to dystonia in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

A 5-year follow-up of deep brain stimulation in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Deep brain stimulation in Huntington's disease: A 4-year follow-up case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Levodopa responsive parkinsonism in an adult with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Seven cases of huntington's disease in childhood and levodopa induced improvement in the hypokinetic — Rigid form

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Long-term follow-up of Huntington disease treated by bilateral deep brain stimulation of the internal globus pallidus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Pramipexole ameliorates neurologic and psychiatric symptoms in a Westphal variant of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Bilateral globus pallidus stimulation in Westphal variant of huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Internal globus pallidotomy in dystonia secondary to Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Cortical myoclonus in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Myoclonus in adult Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Cognitive decline in prodromal Huntington Disease: implications for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Distinct cognitive profiles of cortical and subcortical dementia in advanced illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Patients with Huntington's disease have impaired awareness of cognitive, emotional, and functional abilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Two years' follow-up of rivastigmine treatment in Huntington disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Rivastigmine in the treatment of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Effect of donepezil on motor and cognitive function in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

A pilot study of the clinical efficacy and safety of memantine for Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Neuropsychiatric aspects of Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

21 January 2018

Apathy is not depression

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Cognitive and psychiatric aspects of Huntington disease contribute to functional capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Systematic review of pharmacological treatments for depressive symptoms in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

A controlled trial of fluoxetine in nondepressed patients with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Results of the citalopram to enhance cognition in Huntington disease trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Combating depression in Huntington's disease: effective antidepressive treatment with venlafaxine XR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington's chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Risperidone long-acting injection and Huntington's disease: case series with significant psychiatric and behavioural symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

ECT in genetically confirmed Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

ECT as a treatment for depression in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Rapid improvement of depression and psychotic symptoms in Huntington's disease: a retrospective chart review of seven patients treated with electroconvulsive therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Depression and stages of Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Suicide risk in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Risk factors for suicide in Huntingtons disease: a retrospective case controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Suicidal ideation in Huntington disease: the role of comorbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Treatment of Apathy in Huntington's Disease and Other Movement Disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Fluoxetine in the treatment of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

An International Survey-based Algorithm for the Pharmacologic Treatment of Obsessive-Compulsive Behaviors in Huntington's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Sertraline in the treatment of severe aggressiveness in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

An International Survey-based Algorithm for the Pharmacologic Treatment of Irritability in Huntington's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

The Genetic Modifiers of Motor OnsetAge (GeM MOA) Website: Genome-wide Association Analysis for Genetic Modifiers of Huntington's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Delivering a disease-modifying treatment for Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Therapeutic advances in Huntington's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Huntington disease: pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Neuroprotective and metabolic effects of resveratrol: therapeutic implications for Huntington's disease and other neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Sirtuins: double players in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

A futility study of minocycline in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Antisense oligonucleotides: from design to therapeutic application

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Personalized gene silencing therapeutics for Huntington disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Targets for future clinical trials in Huntington's disease: what's in the pipeline?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Huntingtin-lowering strategies in Huntington's disease: antisense oligonucleotides, small RNAs, and gene editing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Huntington's disease: an update of therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Promising human brain tumors therapy with interference RNA intervention (iRNAi).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Phase I clinical trial of SYL040012, a small interfering RNA targeting β-adrenergic receptor 2, for lowering intraocular pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-017-0739-9

Psychopathology in Verified Huntington's Disease Gene Carriers

21 January 2018

1 reference

12 December 2020

Safety and Efficacy of Tetrabenazine and Use of Concomitant Medications During Long-Term, Open-Label Treatment of Chorea Associated with Huntington's and Other Diseases

1 reference

12 December 2020

Fluphenazine decanoate in the treatment of chorea: a double-blind study

1 reference

12 December 2020

Depressed mood and suicidality in individuals exposed to tetrabenazine in a large Huntington disease observational study

1 reference

12 December 2020

The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease.

1 reference

12 December 2020

Use of risperidone in psychosis associated with Huntington's disease

1 reference

12 December 2020

Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease

1 reference

12 December 2020

Aripiprazole in the treatment of Huntington's disease: a case series

1 reference

12 December 2020

Cognitive function in early clinical phase huntington disease after rivastigmine treatment

1 reference

12 December 2020

Obsessive compulsive disorder in huntington disease: a case of isolated obsessions successfully treated with sertraline.

1 reference

12 December 2020

Huntington's disease: clinical effects of a short-term treatment with pimozide.

1 reference

12 December 2020

Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators

1 reference

12 December 2020

Clinical experience with risperidone and memantine in the treatment of Huntington's disease.

1 reference

12 December 2020

Short-term effects of olanzapine in Huntington disease.

1 reference

12 December 2020

Cabergoline in Huntington's disease: the first case report

1 reference

12 December 2020

Quetiapine in the management of psychosis secondary to huntington's disease: a case report

1 reference

12 December 2020

10.1007/S11910-017-0739-9

Identifiers

DOI

1 reference

9 September 2017

1 reference

PubMed ID

28324302